Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | PRKDC | P78527 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16000561 | 0.98 | MAPT (0.63) | MAPTLMNAPRKDCALDH1A1SMN1; SMN2 | |
| SCHEMBL22904717 | 0.89 | MEN1 (0.58) | MAPTLMNAPRKDCALDH1A1SMN1; SMN2 | |
| SCHEMBL20178041 | 0.87 | HSD11B1 (0.57) | MAPTLMNAPRKDCALDH1A1HTT | |
| SCHEMBL28295817 | 0.84 | MAPT (0.52) | MAPTLMNAPRKDCALDH1A1SMN1; SMN2 | |
| SCHEMBL5738297 | 0.84 | MAPT (0.54) | MAPTLMNAPRKDCALDH1A1SMN1; SMN2 | |
| SCHEMBL14614585 | 0.84 | MAPT (0.52) | MAPTLMNAPRKDCALDH1A1SMN1; SMN2 | |
| SCHEMBL1453639 | 0.84 | MAPT (0.59) | MAPTLMNAPRKDCALDH1A1SMN1; SMN2 | |
| SCHEMBL12744643 | 0.83 | L3MBTL3 (0.54) | MAPTLMNAPRKDCALDH1A1SMN1; SMN2 | |
| SCHEMBL13511002 | 0.83 | PRKDC (0.52) | MAPTLMNAPRKDCALDH1A1SMN1; SMN2 | |
| SCHEMBL23172976 | 0.83 | HSD11B1 (0.50) | MAPTLMNAPRKDCALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 431 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| EP-4279991-A1 | NOVEL SULFONIUM SALT, RESIST COMPOSITION, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-22 | — | — | EP | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| EP-1354887-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | Massachusetts Insitute of Technology (US) | 2003-10-22 | — | — | EP | disclosed |
| WO-2003066570-A1 | TRANSITION-METAL-CATALYZED CARBON-NITROGEN BOND-FORMING METHODS USING CARBENE LIGANDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-1313560-A1 | CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION | YALE UNIVERSITY (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6562989-B2 | Bicyclopentyl iron ligand and transition metal catalyst | YALE UNIVERSITY | 2003-05-13 | — | — | US | disclosed |
| US-20030008768-A1 | Catalyst for aromatic C-O, C-N, and C-C bond formation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| WO-2002011883-A1 | CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION | YALE UNIVERSITY (US) | 2002-02-14 | — | — | WO | disclosed |
| EP-1097158-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000002887-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-01-20 | — | — | WO | disclosed |
| EP-0324791-A1 | ARYL-N-AMINOALKYL-4-(SULFONAMIDO)BENZAMIDES, ANTIARRHYTMIC AGENTS AND COMPOSITIONS THEREOF. | SCHERING AG (DE) | 1989-07-26 | — | — | EP | disclosed |
| WO-1988002362-A1 | ARYL-N-AMINOALKYL-4-(SULFONAMIDO)BENZAMIDES, ANTIARRHYTMIC AGENTS AND COMPOSITIONS THEREOF | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | MAPT 2358/4885LMNA 3263/4885PRKDC 127/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | MAPT 3549/4885LMNA 3425/4885PRKDC 1344/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | MAPT 4491/4885LMNA 2135/4885PRKDC 2052/4885 |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | MAPT 1168/4885LMNA 1338/4885PRKDC 3437/4885 |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | MAPT 1168/4885LMNA 1338/4885PRKDC 3437/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | MAPT 3007/4885LMNA 816/4885PRKDC 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.